MétaCan
Menu
Back to cohort
Record W22838508 · doi:10.1021/nn3021822

Evidence requirements for the authorization and reimbursement of high-risk medical devices in the USA, Europe, Australia and Canada: An analysis of seven high-risk medical devices

2013· article· en· W22838508 on OpenAlexaboutno aff
Lisa J. Krüger, Claudia Wild

Bibliographic record

VenueACS Nano · 2013
Typearticle
Languageen
FieldEconomics, Econometrics and Finance
TopicHealth Systems, Economic Evaluations, Quality of Life
Canadian institutionsnot available
Fundersnot available
KeywordsReimbursementAuthorizationFood and drug administrationMedicineEuropean unionBusinessPrior authorizationMedical emergencyHealth careComputer securityPolitical scienceComputer scienceLawInternational tradeNursing

Abstract

fetched live from OpenAlex

In the last decade, public awareness of unsafe and ineffective high-risk devices entering the market has been raised. Consequently, evidence requirements for the market authorisation process of medical devices may not be enough to ensure high-quality and safe provision of care. This report first explores the authorisation systems for high-risk medical devices in four selected regions (USA, Canada, Australia and Europe). Secondly, it analyses the clinical evidence accessible at the time of both market approval and assessment (HTA) for the reimbursement of seven selected high-risk medical devices. Methods: A literature search in PubMed, complimented by a worldwide web-search, was conducted for authorisation systems and their evidence requirements in the four selected regions, with a focus on seven exemplary high-risk devices. Results: All seven medical devices have been approved in the European Union through an appointed Notified Body, only four by the Australian Therapeutic Goods Administration (TGA), one each by the US-American Food and Drug Administration (FDA) and the Canadian Therapeutics Products Directorate (TPD) respectively. In comparison to the other three regulatory systems, the number of approved devices in Europe is high, especially when taking into additional consideration that four further devices were also assessed by the FDA, but were either rejected or not approved for general use. In almost all of the seven analysed examples, the pre-market approval in Europe was granted 2-5 years before authorisation in other systems. The evidence used for CE-marking is not known due to its highly decentralised authorisation system and the lack of transparency. Since authorisation in Europe is granted earlier, the clinical evidence is naturally less mature. In contrast, none of the seven medical devices has so far been recommended for reimbursement. The pre-reimbursement assessments most often state that current evidence is not enough to ensure patient benefit and safety. Some devices are recommended for research only. Discussion and conclusion: The results support the call for a change in the European authorisation system towards a transparent and evidence-based regulation process. Conditional coverage or coverage under evidence development is applied as an instrument to close the gap between immature data and reimbursement requirements.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.012
metaresearch head score (Gemma)0.069
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: Methods · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.988
Threshold uncertainty score0.380

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0120.069
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0010.002
Bibliometrics0.0050.006
Science and technology studies0.0010.001
Scholarly communication0.0040.001
Open science0.0020.002
Research integrity0.0020.002
Insufficient payload (model declined to judge)0.0050.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.269
GPT teacher head0.416
Teacher spread0.147 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
DomainMethods
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2013
Admission routes1
Has abstractyes

Explore more

Same venueACS NanoSame topicHealth Systems, Economic Evaluations, Quality of LifeFrench-language works237,207